Bexsero + routine vaccines

Bexsero (4CMenB) is a multicomponent vaccine developed by Novartis Vaccines (now part of GSK) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B. The vaccine contains four main antigenic components: three recombinant proteins (factor H binding protein [fHbp], Neisseria adhesin A [NadA], and Neisseria heparin binding antigen [NHBA]) and outer membrane vesicles (OMV) from the New Zealand epidemic strain NZ98/254, which provides the PorA P1.4 antigen. The 'routine + rMenB+OMV NZ' designation specifically refers to the co-administration of Bexsero with standard pediatric routine vaccines (such as DTaP, Hib, IPV, and MMR) in clinical trial settings to evaluate the safety, tolerability, and immunogenicity of the vaccine when integrated into the standard infant and toddler immunization schedule. Bexsero works by inducing serum bactericidal antibodies that target these surface antigens, leading to the complement-mediated killing of the bacteria.

Brand names

Bexsero

Other names

Novartis Meningococcal B Recombinant VaccineMeningococcal Group B Vaccine (Recombinant, Adsorbed)